Julie Rubinstein, President and COO of Adaptive Biotechnologies (NASDAQ: ADPT), sold 81,342 shares of common stock for approximately $1.21 million between March 6 and March 10, 2026. This transaction, executed under a pre-established 10b5-1 trading plan, reduced her direct holdings by 11.22%, leaving her with 643,471 shares. The sale included shares from the exercise of stock options and an equity award, with a weighted average sale price of $14.90, significantly above the exercise prices of $6.55 and $12.14.
This sale comes as Adaptive Biotechnologies has seen its stock rise about 118% over the past year, although recent performance has cooled slightly. The company reported a 46% revenue growth in its Minimal Residual Disease (MRD) segment in 2025 and is guiding for positive adjusted EBITDA and free cash flow by the end of 2026, indicating a strong business trajectory.
Investors should note that while Rubinstein’s sale represents a liquidity event, it does not signal a loss of confidence in the company’s future prospects, especially given the promising growth in its core product offerings.
Source: nasdaq.com